Truist analyst David MacDonald raised the firm’s price target on Encompass Health to $75 from $70 and keeps a Buy rating on the shares after its Q4 earnings beat. The company saw a solid close to the year as volumes remained strong and its adjusted EBITDA came in ahead of estimates, the analyst tells investors in a research note. Encompass also continues to see progress on the labor front, and its FY23 guidance is seen as a "solid starting point", the firm adds.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on EHC:
- Encompass Health price target raised to $69 from $65 at Mizuho
- Encompass Health price target raised to $73 from $62 at Credit Suisse
- Encompass Health price target raised to $73 from $68 at UBS
- Encompass Health sees FY23 adjusted EPS $2.87-$3.16, consensus $3.25
- Encompass Health reports results for fourth quarter 2022 and issues full-year 2023 guidance
